Press Releases

Date Title and Summary Additional Formats
Toggle Summary Assembly Biosciences Announces the Closing of its Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
INDIANAPOLIS and SAN FRANCISCO , July 16, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock to the public at $36.00 per share, which included
View HTML
Toggle Summary Assembly Biosciences Announces Pricing of $144 Million Offering of Common Stock
INDIANAPOLIS and SAN FRANCISCO , July 11, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock to the public at $36.00 per share.
View HTML
Toggle Summary Assembly Biosciences Announces Proposed Underwritten Offering of Common Stock
INDIANAPOLIS and SAN FRANCISCO , July 10, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced that it intends to offer and sell, subject to market and other conditions, 3,000,000 shares of its common stock in an underwritten public offering.
View HTML
Toggle Summary Assembly Biosciences Initiates Two Phase 2a Trials of ABI-H0731 for the Treatment of Hepatitis B Virus Infection
Key aim is to demonstrate that core inhibitor therapy combined with standard of care antivirals can offer curative potential for HBV INDIANAPOLIS and SAN FRANCISCO, July 09, 2018 (GLOBE NEWSWIRE) --   Assembly Biosciences, Inc.  (Nasdaq:ASMB), today announced the initiation of two multi-center,
View HTML
Toggle Summary Assembly Biosciences to Host Research and Development Day on Wednesday, June 20, 2018
Live event and webcast to focus on the potential of curative therapy for HBV infection and feature presentations from two liver medicine specialists INDIANAPOLIS and SAN FRANCISCO, June 13, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences , Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company
View HTML
Toggle Summary Assembly Biosciences Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
INDIANAPOLIS and SAN FRANCISCO , June 08, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral synthetic live biotherapeutics for
View HTML
Toggle Summary Assembly Biosciences to Participate in Jefferies 2018 Global Healthcare Conference
INDIANAPOLIS and SAN FRANCISCO , June 04, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral synthetic live biotherapeutics for
View HTML
Toggle Summary Assembly Biosciences Announces First Quarter 2018 Financial Results
INDIANAPOLIS and SAN FRANCISCO , May 07, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral synthetic live biotherapeutics for
View HTML
Toggle Summary Assembly Biosciences Presents Positive Interim Data from Phase 1a and 1b Studies of ABI-H0731 in HBV Patients in a Late-Breaker Session at the EASL Conference
Robust antiviral activity observed in HBV patients Generally safe and well tolerated Planning underway for Phase 2a studies beginning summer 2018 Company to host conference call on Thursday, April 12 th at 8am ET / 2pm CEST INDIANAPOLIS and SAN FRANCISCO , April 12, 2018 (GLOBE NEWSWIRE) --
View HTML
Toggle Summary Assembly Biosciences to Host Conference Call on April 12 to Review ABI-H0731 Interim Phase 1b Data in HBV Patients Featured in Late-Breaker Poster at EASL
INDIANAPOLIS and SAN FRANCISCO , April 10, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders
View HTML